About Horizon Therapeutics
Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. We are creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
HZT-501: Positive Phase 3 Data
The two pivotal trials are complete and have met their primary endpoints
Latest News
10.21.09AGA Institute and Horizon Therapeutics Expand CONNECT to Protect Program to Educate Consumers on NSAID Risk06.01.09
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients with Mild-to-Moderate Pain